An interventional study of Immuno analytical assay in Malaria, sponsored by University of Ghana. Active, not recruiting at 1 site in Ghana. Per ClinicalTrials.gov, last updated 2023-12-01.
Sponsored by University of Ghana · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies in Malaria with a site in Ghana — 5 open to participants now, 6 under way, none of them phase 3. Malaria · Ghana.
Among the 59 studies in Malaria with a site in Ghana, this one is the 22nd largest by enrollment of the 47 interventional ones that give a count, is the only one that started in 2022, is one of 14 with no phase, and was the 55th registered.
1,187 studies on the registry are indexed under Malaria; 80 are open to participants now.
Browse Malaria studies →5 of the 59 studies in Malaria with a site in Ghana are open now. Recruiting first, the newest first:
University of Michigan · Sites in Ghana
Ages 15–49 · Women only · Healthy volunteers
Novartis Pharmaceuticals · Sites in Ghana, Burkina Faso, Côte D'Ivoire and 3 more countries
Ages 2–100
Noguchi Memorial Institute for Medical Research · Sites in Ghana
Ages 3 mo+ · Healthy volunteers
Kintampo Health Research Centre, Ghana · Sites in Ghana, Kenya, Malawi
Ages 6 mo–59 mo
Bernhard Nocht Institute for Tropical Medicine · Sites in Ghana
Ages 18+ · Women only · Healthy volunteers
A study can be open while its sites in Ghana have not opened yet or have stopped. Only those recruiting at a site in Ghana →
Of the 51 Malaria studies recruiting now, 15 (29%) set no upper age limit and 33 (65%) stop at 75 or younger; 37 take children under 18; 31 take healthy volunteers.
This study: all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 15 · Phase 4 12
First in 2000; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,640 is above the median of 252 across 939 interventional studies indexed under Malaria.
Median enrollment 1,490 across the 47 interventional studies, 1,800 across the 11 observational. Of the 48 that completed or were terminated, 16 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 59 have an industry lead sponsor. The 10 most frequent:
University of Ghana is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
University of Ghana has 2 studies filed under Malaria — fewer than ten, so there is no comparison to draw.
1 of the studies in Malaria with a site in Ghana that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07389057Noguchi Memorial Institute for Medical ResearchAssessing the Feasibility of Combining Dihydroartemisinin Piperaquine and Primaquine for Malaria Mass Drug Administration in High Endemic Communities in the Eastern Region of Ghana | 2026-11-30 |
Add it to your calendar (.ics) → With an account.
Among the 59 studies in Malaria with a site in Ghana, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to develop immuno-analytical assays for testing the titres of malaria antibodies in Ghanaian patients' and/or donors' sera using a recombinantly produced MSP119 fusion protein and/or MSP119-derived synthetic peptides as antigens.
In this study, immuno-analytical assays will be developed for determining the titres of malaria antibodies in sera of two groups (malaria patients and donors/healthy volunteers) using a recombinantly produced MSP119 fusion protein and/or MSP119-derived synthetic peptides as antigens. Individuals in the two groups presenting to Shai-Osudoku District hospital will be screened for signs and symptoms of malaria according to the WHO criteria. Those within the inclusion and exclusion criteria will be introduced to the study through informed consent for adults (18 years and over) or parents/guardians for children below 12 years and assent for adolescents between 12 and below 18 years, along with informed consent from their parents. Enrolled study participants' demographic data and vital signs will be captured electronically onto the CRF. Patients will have their clinical history and detailed physical examination done by the study clinicians and then be sent to the laboratory for investigations to confirm the malaria diagnosis. The results of patients will be communicated to the study clinician to commence the appropriate treatment. At the of the study, the results of all assays will be analyzed to determine if this test can be used to diagnose malaria infection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malaria patients
Diagnostic Test: Immuno analytical assay
Healthy individuals (donors; controls)
Diagnostic Test: Immuno analytical assay
The eluted antibodies will be used in immuno-analytical assays, such as ELISA or Western blot, or surface-coated bead-based screening platforms using either recombinantly produced MSP119 fusion protein or synthetic peptides derived from MSP119 as antigens according to standard protocols.
MSP1-19 malaria antigen
Number of participants with MSP1-19 malaria antigen as assessed by a lateral flow test kit.
Time frame: one year
Anti-MSP1-19 malaria antibody
Number of participants with antiMSP1-19 malaria antibody as assessed by a lateral flow test kit.
Time frame: three years
Plan to share: Yes — Data will be deposited in Zenodo's open data repository service (CERN). Additionally, all datasets will be stored on external drives and in-house computers. The data will be deposited as soon as possible unless there is a legitimate reason and a decision has been agreed upon to protect the data. Before the upload of datasets, a unique DOI will be assigned, which will be stated in publications to direct readers to the primary datasets. Due to the public health interest of the outcome of this work, the datasets will be shared directly with relevant stakeholders for a wider public audience. There will be restricted datasets on the subject partaking in the study to protect their identity. This restriction will not affect the dissemination of the research outputs to the broader public. Although the datasets will be stored in the Zenodo repository for long-term preservation, the in-house datasets will be stored on an external drive for additional long-term benefit.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Five years
Access criteria: The IPD can be accessed by requesting the Principal Investigator or accessing the information directly from Zenodo's open data repository service.
No publications or documents are linked to this record.
Started Sep 2022 (actual). Primary completion is estimated for Sep 2024, 24 months after the start.
Of 96 non-industry interventional studies with no phase under Malaria, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's planned 24 months is close to that.
Counting every sponsor, half of 102 studies reached it within 23 months; a quarter within 8 and three quarters within 33.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Ghana